Navigation Links
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
Date:12/9/2011

SINGAPORE, Dec. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it will issue US$1,110,000 worth of shares of its common stock to AIM-listed company, ValiRx PLC.  The share issuance is the final requirement of the Share Purchase Agreement dated 22 September 2010 (as amended on 9 June 2011) between ValiRx and Singapore Volition Pte Limited, a subsidiary of VolitionRX.

Volition will issue 525,000 restricted shares of common stock to ValiRx. Of that number of shares, 14,189 shares will be issued directly to Chroma Therapeutics Limited of Abingdon, Oxfordshire, UK, as payment for the direct licensing of Chroma Therapeutics's patent "Detection Of Histone Modifications In Cell-Free Nucleosomes" to Singapore Volition.

Cameron Reynolds, CEO of VolitionRX, said, "We're grateful to ValiRx for their advice and support over the last 15 months, and are therefore delighted to make this final payment of shares to ValiRx. We're also happy to be issuing shares as royalty to Chroma Therapeutics, whose patent forms a significant part of our technology portfolio."

About VolitionRX
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX is managed by a well-respected team with extensive experience in diagnostics and commercialization. VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

VolitionRX is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

 


'/>"/>
SOURCE VolitionRX Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
2. VolitionRX Limited Issues Update Letter to Shareholders
3. Ansell Limited Acquires a Minority Share in Yulex Corporation
4. RSNA 2011: Ziehm Imaging Presents Innovative Mobile C-Arms for Virtually Unlimited Imaging
5. Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
6. Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives
7. Express Scripts HealthBridge Pharma & Biotech to Provide Exclusive Specialty Pharmacy Services and Limited Distribution Services for Solesta®
8. BD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative®
9. Panacea Global, Inc. Signs Multi-year Contract Valued at Minimum $8.75 Million for Cancer Detection System with Palmverse Limited
10. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
11. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As ... showcase its anatomic and molecular pathology workflow solution, as well as its new ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton ... families and business owners in the greater Fort Lauderdale metropolitan region, is embarking ... For more than 30 years, LifeNet 4 Families has provided a broad range ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer ... their final treatments. Physician researchers at The Marcus Institute of Integrative Health ... for efficacy in reducing symptoms of traumatic stress in cancer patients and ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... planning services to families and entrepreneurs in the Birmingham area, is announcing an ... who needs assistance with her medically challenged son, Anius. , Anius is medically ...
Breaking Medicine News(10 mins):